Pancreatic Cancer Market Outlook

Thelansis’s “Pancreatic Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pancreatic Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Pancreatic Cancer Overview

Pancreatic Cancer, predominantly manifesting as pancreatic ductal adenocarcinoma, is an exceptionally aggressive and highly lethal gastrointestinal malignancy originating from the exocrine ductal epithelium of the pancreas. Characterized by rapid local invasion, an intense treatment-resistant desmoplastic stroma, and early systemic dissemination, its oncogenic landscape is heavily driven by near-ubiquitous somatic mutations in KRAS, alongside loss-of-function alterations in TP53, SMAD4, and CDKN2A. Patients present insidiously with painless obstructive jaundice, profound cachexia, gnawing epigastric pain radiating to the back, and new-onset atypical type 2 diabetes. Diagnosis relies on multi-detector contrast-enhanced CT or MRI to determine vascular resectability, combined with endoscopic ultrasound-guided fine-needle aspiration for histopathological validation and baseline serum CA19-9 biomarker tracking. Because fewer than 20% of cases are anatomically resectable at presentation, multi-agent systemic chemotherapy remains the absolute backbone of management. Frontline standard-of-care frameworks for advanced disease in 2026 utilize the liposomal irinotecan-based triplet NALIRIFOX or modified FOLFIRINOX for robust performance status cohorts, reserving gemcitabine plus nab-paclitaxel for more fragile patients. Maintenance targeted therapy with the PARP inhibitor olaparib is strictly prioritized for patients harboring germline BRCA1/2 mutations following platinum induction, while novel inhibitors targeting KRAS G12C or G12D variants define the active clinical trial frontier. Overall prognosis remains exceptionally constrained, with a 5-year survival rate hovering near 13%, mandating immediate molecular profiling, early biliary decompression, and dedicated pancreatic enzyme replacement therapy alongside comprehensive palliative integration.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)